TITLE

Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy

AUTHOR(S)
Garcia, David
PUB. DATE
March 2008
SOURCE
ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the randomized controlled trial (RCT) investigating how pharmacogenetic-guided dosing (PGD) and standard dosing (SD) compare for percentage of out-of-range international normalized ratios (INRs) in patients initiating oral anticoagulation with warfarin. The trial, conducted with 206 patients (18 to 86 years of age) found out that PGD and SD did not differ for out-of-range INRs in patients initiating warfarin therapy.
ACCESSION #
32435142

 

Related Articles

  • Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question. Cavallari, L H; Nutescu, E A // Clinical Pharmacology & Therapeutics;Jul2014, Vol. 96 Issue 1, p22 

    Genotype is well recognized to influence the dose of warfarin necessary for therapeutic anticoagulation. Recent randomized controlled trials evaluating the clinical utility of genotype-guided warfarin dosing have produced varying results. We review the design and results of the recent clinical...

  • Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy.  // Evidence Based Medicine;Apr2008, Vol. 13 Issue 2, p55 

    STUDY DESIGN Design: randomised controlled trial (RCT). Allocation: unclear allocation concealment. Blinding: blinded (clinicians and patients). STUDY QUESTION Setting: anticoagulation clinic at Intermountain Healthcare, Utah, United States. Patients: 206 patients 18-86 years of age (mean age 61...

  • DOSING CONVERSION FOR ANTICOAGULANTS: DABIGATRAN/HEPARIN/WARFARIN.  // Monthly Prescribing Reference;Jun2012, Vol. 28 Issue 6, p48 

    The article presents suggestions on dosing conversion for anticoagulants including dabigatran, heparin, and warfarin. It mentions that starting time of warfarin based on creatinine clearance (CrCl) should be adjusted, when switching from dabigatran to warfarin. It advices to adjust starting time...

  • Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. Tang, H L; Shi, W L; Li, X G; Zhang, T; Zhai, S D; Xie, H G // Pharmacogenomics Journal;Dec2015, Vol. 15 Issue 6, p496 

    In terms of inconsistent conclusions across all relevant randomized controlled trials (RCTs) and available meta-analyses, we aimed to use a meta-analysis and trial sequential analysis (TSA) to evaluate whether clinical utility of a genotype-guided warfarin initiation dosing algorithm could be...

  • COMMENTARY. Garcia, David // Evidence Based Medicine;Apr2008, Vol. 13 Issue 2, p55 

    The article comments on the study by J. L. Anderson and colleagues on randomized controlled trial (RCT) of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. According to the author, the results of RCT emphasize the need for caution before adopting...

  • RCT data not to be RE-LYed on, `real-world' NOAC users older.  // PharmacoEconomics & Outcomes News;11/2/2013, Issue 690, p6 

    The article discusses a study by Y Xu et al. which appeared in the October 16, 2013 issue of "Canadian Medical Association Journal (CMAJ)," showing that prescriptions for novel oral anticoagulants (NOACs) have quickly developed since dabigatran was approved for the prevention of stroke in...

  • Flexible induction dose regimen for warfarin and prediction of maintenance dose. Fennerty, A.; Dolben, J.; Thomas, P.; Backhouse, G.; Bentley, D.P.; Campbell, I.A.; Routledge, P.A. // British Medical Journal (Clinical Research Edition);4/28/1984, Vol. 288 Issue 6426, p1268 

    Examines the maintenance of warfarin dose based on prothrombin time. Demonstration of safety anticoagulation; Measurement of dosage during the induction phase; Concerns on the danger of overanticoagulation and sensitivity.

  • Lack of an antagonist to reverse the action of dabigatran. Jolobe, O.M.P. // QJM: An International Journal of Medicine;Feb2012, Vol. 105 Issue 2, p212 

    No abstract available.

  • Another Warfarin Replacement on Horizon. Elliott, William T. // Neurology Alert;Jan2011 Phamacology Watch, p1 

    The article discusses the Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared With Warfarin in Patients with Nonvalvular Atrial Fibrillation (ROCKET AF) study which revealed the efficacy of rivaroxaban as another warfarin replacement for preventing stroke and blood...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics